Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
Atis Tibetan (Aconitum heterophyllum) contains non-toxic diterpenoid alkaloids, primarily atisine and heteratisine, which differ significantly from the toxic alkaloids found in other Aconitum species. These compounds exhibit antipyretic, anti-inflammatory, and antimicrobial properties that help reduce fever, treat diarrhea, and combat parasitic infections. Unlike toxic aconite species, Atis does not affect cardiac sodium channels in a harmful manner, making it therapeutically valuable without cardiotoxic risks. The herb also appears to support digestive function through bitter tonic action. Evidence level: C, based primarily on traditional use and phytochemical analysis rather than clinical trials.
Does Atis Tibetan interact with any medications?
Currently, there are no well-documented drug interactions for Atis Tibetan (Aconitum heterophyllum) in the scientific literature. Unlike toxic Aconitum species that can dangerously potentiate cardiac medications, Atis contains non-toxic alkaloids that do not carry the same interaction risks. However, due to limited clinical research (Evidence level: C), individuals taking prescription medications should consult a healthcare provider before combining treatments. As a general precaution, separate administration of herbal supplements from prescription medications by at least two hours. Those on antipyretic or antidiarrheal medications should monitor for additive effects.
What is the recommended dosage for Atis Tibetan powder?
The standard adult dosage for Atis Tibetan (Aconitum heterophyllum) powder is 1-3 grams daily, traditionally divided into two or three doses. This dosage is based on Ayurvedic and Tibetan medicine practice rather than modern clinical trials (Evidence level: C). The powder can be mixed with warm water or honey for easier consumption. For acute conditions such as fever or diarrhea, practitioners may recommend the higher end of the dosage range. Start with the lowest effective dose and consult a qualified herbalist for personalized recommendations, particularly for elderly individuals or those with chronic health conditions.
Is Atis Tibetan safe to take during pregnancy?
Atis Tibetan (Aconitum heterophyllum) is considered safe during pregnancy according to traditional Ayurvedic and Tibetan medicine texts. Unlike other Aconitum species that are strictly contraindicated in pregnancy due to toxic alkaloids, Atis contains non-toxic diterpenoid alkaloids that do not pose risks to fetal development. This safety profile is based on traditional use rather than controlled clinical studies (Evidence level: C). Pregnant women should still consult a qualified healthcare provider before using Atis Tibetan and should use the lowest effective dose. No adverse pregnancy outcomes have been reported in traditional use literature.
Is Atis Tibetan safer than other aconite species?
Yes, Atis Tibetan (Aconitum heterophyllum) is significantly safer than other Aconitum species such as Aconitum napellus or Aconitum ferox. While most aconite species contain highly toxic alkaloids like aconitine that can cause cardiac arrhythmias and respiratory failure, Atis contains non-toxic diterpenoid alkaloids including atisine, heteratisine, and histisine. This fundamental chemical difference makes Atis one of the few Aconitum species safe for internal medicinal use. Side effects are typically limited to mild gastrointestinal upset in sensitive individuals. Proper identification by a qualified source is essential, as confusing Atis with toxic aconite species could have serious health consequences. Evidence level: C.
Fiche d'information compilée à partir de PubMed
Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.
Compilé à partir de 30 articles PubMed · modèle : gemma4:31b
Résumé
Aconitum heterophyllum (Ativisha) is a critically endangered Himalayan medicinal herb used in Ayurveda, noted for being the only nonpoisonous member of the Aconitum genus [PMID:34996731].
Contexte
Aconitum heterophyllum, also known as Ativisha or Patis, is a rare perennial herb from the northwestern and eastern Himalayas belonging to the Ranunculaceae family [PMID:22556788, PMID:25878466, PMID:34996731, PMID:36738364]. It is considered a critically endangered species [PMID:34996731].
Usages traditionnels
Traditionally used in Ayurveda for treating diarrhea, fever, urinary infections, inflammation, worm infestations, respiratory tract diseases, vomiting, diabetes, skin disorders, anaemia, joint disorders, and as an expectorant [PMID:30087784, PMID:34942322]. It is also used for hysteria, throat infections, dyspepsia, and abdominal pain [PMID:24550590].
Composés actifs
The plant contains alkaloids (specifically aconites such as atisine, aconitine, hypaconitine, mesaconitine, aconine, benzoylmesaconitine, benzoylaconine, bulleyaconitine A, and deoxyaconitine), carbohydrates, proteins, amino acids, saponins, glycosides, quinones, flavonoids, and terpenoids [PMID:30087784, PMID:35794832]. Diterpenoid alkaloids such as heterophyllinine-A and heterophyllinine-B have also been isolated [PMID:18615279, PMID:28457693].
Mécanisme d'action
The herb demonstrates anticholinesterase potential by inhibiting butyrylcholinesterase (BChE) and acetylcholinesterase (AChE) [PMID:18615279, PMID:28457693]. In breast cancer cell lines (MDA-MB-231), it has been shown to upregulate p53 and p21 while downregulating BCL2 and STAT [PMID:37538242]. It also exhibits hypolipidemic effects by lowering total cholesterol, triglycerides, and apolipoprotein B, while increasing serum high-density lipoprotein [PMID:23378943].
Preuves cliniques
Preuve DDiarrhea
Ethanol extract significantly reduced normal fecal output and demonstrated antisecretory and antimotility activity in animal models [PMID:24550590, PMID:25130980]
Preuve DObesity/Hyperlipidemia
Methanol fraction markedly lowered total cholesterol, triglycerides, and apolipoprotein B in diet-induced obese rats [PMID:23378943]
Preuve DAcute Renal Failure
Ethanolic root extract showed antioxidant and nephroprotective activities in glycerol-induced acute renal failure in rats [PMID:27134892]
Preuve DBreast Cancer
Root extract showed anti-proliferative potential in human MDA-MB-231 cell lines [PMID:37538242]
Preuve DProstate Enlargement
Did not show any significant effect on prostatic hyperplasia induced in rats [PMID:24761116]
Preuve BInfant Immunity
Used as part of 'Bala compound' oral drops to assess effects on serum immunoglobulins IgG, IgM, and IgA [PMID:22557316]
Sécurité et effets indésirables
A. heterophyllum is described as the only nonpoisonous member of the Aconitum genus [PMID:34996731]. A formulation containing A. heterophyllum (Balacaturbhadrika churna) showed no signs of toxicity or mortality in rats up to a dose of 2000 mg/kg in acute studies, nor significant effects at 900 mg/kg over 45 days [PMID:21760693].
Synthèse des preuves
The evidence consists primarily of in vitro studies and animal models (Level D), with limited clinical observation in pediatric formulations (Level B). Most data are derived from reviews of traditional use or preliminary pharmacological screenings.
Sources PubMed
1.PMID: 22556788 (1996) — Aconitum heterophyllum (ativisha) in ayurveda. · Ancient science of life
2.PMID: 26167002 (2015) — Pharmacology of Ativisha, Musta and their substitutes. · Journal of Ayurveda and integrative medicine
3.PMID: 25878466 (2015) — Abhava pratinidhi dravya: A comparative phytochemistry of Ativisha, Musta and related species. · Journal of Ayurveda and integrative medicine
4.PMID: 33262017 (2022) — Understanding COVID - 19 pandemic - A comprehensive Ayurvedic perspective. · Journal of Ayurveda and integrative medicine
5.PMID: 30087784 (2017) — Primary Pharmacological and Other Important Findings on the Medicinal Plant "Aconitum Heterophyllum" (Aruna). · Journal of pharmacopuncture
Sources gouvernementales
Aucune monographie gouvernementale directe n'est disponible pour cette plante. Le contenu ci-dessous est généré par IA et n'a pas été vérifié par rapport à une source gouvernementale faisant autorité. Utilisez les liens de recherche pour consulter les sources officielles avant de vous fier à ces informations.
6.PMID: 34996731 (2022) — Aconitum heterophyllum Wall. ex Royle: A critically endangered medicinal herb with rich potential for use in medicine. · Journal of integrative medicine
7.PMID: 24761116 (2014) — Inhibitory effects by ayurvedic plants on prostate enlargement induced in rats. · Pharmacognosy research
8.PMID: 34942322 (2022) — Antiplasmodial diterpenoid alkaloid from Aconitum heterophyllum Wall. ex Royle: Isolation, characterization, and UHPLC-DAD based quantification. · Journal of ethnopharmacology
9.PMID: 24128578 (2014) — nrDNA ITS sequence based SCAR marker to authenticate Aconitum heterophyllum and Cyperus rotundus in Ayurvedic raw drug source and prepared herbal products. · Food chemistry
10.PMID: 37538242 (2023) — Anti-proliferative potentials of Aconitum heterophyllum Root Extract in Human Breast cancer (MDA-MB-231) cell lines-Genetic and Antioxidant enzyme approach. · Avicenna journal of medical biotechnology
11.PMID: 24550590 (2014) — Antisecretory and antimotility activity of Aconitum heterophyllum and its significance in treatment of diarrhea. · Indian journal of pharmacology
12.PMID: 22557316 (2009) — Clinical study of the Immunoglobululin Enhancing effect of "Bala compound" on Infants. · Ancient science of life
13.PMID: 21829299 (2010) — Cyperus rotundus, a substitute for Aconitum heterophyllum: Studies on the Ayurvedic concept of Abhava Pratinidhi Dravya (drug substitution). · Journal of Ayurveda and integrative medicine
14.PMID: 28457693 (2017) — Antioxidant and anticholinesterase potential of diterpenoid alkaloids from Aconitum heterophyllum. · Bioorganic & medicinal chemistry
15.PMID: 38995530 (2024) — Airways Relaxant and Antiasthmatic Activity of Aconitum heterophyllum Wall ex Royle. Roots: A Mechanistic Insight. · Cell biochemistry and biophysics
16.PMID: 25130980 (2014) — Cryptocoryne spiralis, a substitute of Aconitum heterophyllum in the treatment of diarrhoea. · The Journal of pharmacy and pharmacology
17.PMID: 21760693 (2011) — Toxicological study of Balacaturbhadrika churna. · Journal of Ayurveda and integrative medicine
18.PMID: 23378943 (2012) — Hypolipidemic effect of methanol fraction of Aconitum heterophyllum wall ex Royle and the mechanism of action in diet-induced obese rats. · Journal of advanced pharmaceutical technology & research
19.PMID: 37951375 (2024) — Ethnopharmacologically important highly subsidized Indian medicinal plants: Systematic review on their traditional uses, phytochemistry, pharmacology, quality control, conservation status and future prospective. · Journal of ethnopharmacology
20.PMID: 36519419 (2023) — Insecticidal potential of extracts, fractions, and molecules of Aconitum heterophyllum Wall ex. Royle against aphid Aphis craccivora Koch (Hemiptera: Aphididae). · Pest management science
21.PMID: 35794832 (2022) — Identification and quantification of eight alkaloids in Aconitum heterophyllum using UHPLC-DAD-QTOF-IMS: A valuable tool for quality control. · Phytochemical analysis : PCA
22.PMID: 25239552 (2014) — Multiple genes of mevalonate and non-mevalonate pathways contribute to high aconites content in an endangered medicinal herb, Aconitum heterophyllum Wall. · Phytochemistry
23.PMID: 34513611 (2022) — The dual role of phytochemicals on SARS-CoV-2 inhibition by targeting host and viral proteins. · Journal of traditional and complementary medicine
24.PMID: 27134892 (2016) — Antioxidant and Nephroprotective Activities of Aconitum heterophyllum Root in Glycerol Induced Acute Renal Failure in Rats. · Journal of clinical and diagnostic research : JCDR
25.PMID: 3560991 (1986) — Immunomodulating agents of plant origin. I: Preliminary screening. · Journal of ethnopharmacology
26.PMID: 18615279 (2009) — New diterpenoid alkaloids from Aconitum heterophyllum Wall: Selective butyrylcholinestrase inhibitors. · Journal of enzyme inhibition and medicinal chemistry
27.PMID: 38947854 (2024) — Insights into Metabolites Profiling and Pharmacological Investigation of Aconitum heterophyllum wall ex. Royle Stem through Experimental and Bioinformatics Techniques. · ACS omega
28.PMID: 36738364 (2023) — Molecular characterization of fungal endophyte diversity isolated from Aconitum heterophyllum: a critically endangered medicinal plant of Kashmir Himalaya. · International microbiology : the official journal of the Spanish Society for Microbiology
29.PMID: 37355080 (2023) — Medicinal plants traditionally used in the health care practices by the indigenous communities of the Trans-Himalayan region of Ladakh, India. · Journal of ethnopharmacology
30.PMID: 32624610 (2020) — Anti-obesity efficacy of the selected high altitude Himalayan herbs: in vitro studies. · Journal of food science and technology